ANTISENSE TECHNOLOGY

ANTISENSE TECHNOLOGY

An antisense oligonucleotide (ASO) is a single-stranded deoxyribonucleotide, which is complementary to the mRNA target. The goal of the antisense approach is the downregulation of a molecular target, usually achieved by induction of RNase H endonuclease activity that cleaves the RNA-DNA heteroduplex with a significant reduction of the target gene translation . Other ASO-driven mechanisms include inhibition of 5′ cap formation, alteration of splicing process (splice-switching), and steric hindrance of ribosomal activity .

Drug

# There are six FDA-approved drugs based on oligonucleotide therapy:-

(1) fomivirsen for treatment of CMV retinitis in AIDS patients.

(2) mipomersen for treatment of familial hypercholesterolemia.

(3) Defibrotide for treatment of veno-occlusive disease in the liver.

(4) eteplirsen for the treatment of Duchenne muscular dystrophy.

(5) pegaptanib for the treatment of neovascular age-related macular degeneration.

(6) nusinersen for the management of spinal muscular atrophy.



Comments

Post a Comment

Popular posts from this blog

Subject: Request for Permission to Keep a Small Beard

 **Subject: Request for Permission to Keep a Small Beard** Dear Sir, I hope this letter finds you in good health. I am writing to formally request permission to maintain a small beard due to my personal and religious beliefs. I understand the importance of maintaining a professional appearance at the workplace and assure you that my beard will be kept neat and well-groomed, in accordance with company standards. I kindly ask for your consideration and approval of this request, and I am more than willing to discuss any concerns you may have. Thank you for your understanding and support. Sincerely,   Mohd Aasif   Executive  Cadila Pharmaceutical Pvt Ltd   23 October 2024 **Subject: Request for Approval to Maintain a Small Beard** Dear [Manager's Name], I hope you are doing well. I am writing to request permission to maintain a small beard, in line with my personal and religious practices. I fully respect the company’s appearance policies and will ens...
Read more

article review on tocilizumab production

Tocilizumab (Actemra) is a humanized monoclonal antibody that targets the interleukin-6 (IL-6) receptor, which is involved in the inflammatory response. It is used to treat rheumatoid arthritis, systemic juvenile idiopathic arthritis and other inflammatory conditions. It is produced using recombinant DNA technology in Chinese hamster ovary (CHO) cells. One research article "Development of an efficient and scalable fed-batch culture process for the production of tocilizumab in Chinese hamster ovary cells" by Li et al. (2019) aimed to optimize the production of tocilizumab using a fed-batch cultivation system in CHO cells. The study aimed to improve the yield and quality of the protein, and to develop a process that can be easily scaled up for industrial production. The results of the study showed that the yield of tocilizumab was significantly improved by optimizing the culture conditions, such as the temperature, pH, and dissolved oxygen, as well as by using a specific ...
Read more

effect of ph on rituximab production

The pH of the culture medium is an important parameter that affects the growth and productivity of cells in a bioreactor. The pH can affect the solubility, stability and activity of enzymes, as well as the uptake and metabolism of nutrients. In the case of rituximab production, the pH can affect the stability and activity of the protein, as well as the productivity of the cells. Optimal pH for rituximab production in Chinese hamster ovary (CHO) cells usually ranges from 7.0 to 7.5. A pH that is too low or too high can cause the protein to denature or aggregate, reducing its activity and stability. Additionally, a pH that is too low or too high can also cause stress to the cells, reducing their productivity. A research article "Development of a high-titer, high-density fed-batch process for the production of Rituximab in Chinese Hamster Ovary (CHO) cells" by Wang et al. (2015) aimed to improve the production of rituximab by developing a high-titer and high-density fed-batc...
Read more